Journal of clinical and experimental hepatology · 2026
Effect of Blood Group on von Willebrand Factor Antigen Levels in Compensated Advanced Chronic Liver Disease and Utility of von Willebrand Factor-Platelet Ratio for Detecting Clinically Significant Portal Hypertension.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Sharma Ritesh, Ray Debadrita, De Arka, Shastri Arpit, Lamba Divjot S, Bhagat Naveen, Verma Nipun, Taneja Sunil, Kumar Mahinder, Bhujade Harish, Kalra Naveen, Kumar Narender, Ahluwalia Jasmina, Duseja Ajay
Аннотация
BACKGROUND/PURPOSE: In the general population, von Willebrand Factor (vWF) antigen levels are 20-30% lower in blood group O. However, the effect of blood group O on vWF antigen in compensated advanced chronic liver disease (cACLD) is unknown. Furthermore, there are limited data comparing vWF with elastography for assessment of clinically significant portal hypertension (CSPH). We assessed the effect of blood group O on vWF antigen levels, and the discriminative ability of vWF-platelet ratio (VITRO) for assessment of CSPH in comparison to liver stiffness measurement (LSM) on elastography in cACLD.
METHODS: One hundred patients with cACLD were prospectively included. Hemogram, blood biochemistry, plasma vWF antigen levels, computed tomography abdomen, LSM with vibration-controlled transient elastography and endoscopic screening for varices were performed. CSPH was defined by the presence of collaterals on imaging, varices on endoscopy or portosystemic pressure gradient >10 mmHg.
RESULTS: vWF antigen levels were comparable between blood group O and non-O (282.9 ± 44.6% vs 289.9 ± 86.3%, P = 0.60). vWF: antigen had significant correlation with LSM [rho:0.65 (95% confidence interval (CI): 0.48-0.75, P < 0.001)] and portosystemic pressure gradient [rho = 0.60 (95% CI: 0.27-0.81, P < 0.001)].Areas under the curves (AUROCs) of LSM (0.878, 95% CI: 0.747-0.980) and VITRO (0.881, 95% CI: 0.745-0.982, P = 0.95) were comparable for detecting CSPH. Optimal VITRO rule-out and rule-in cut-offs for CSPH were <1.14 [sensitivity 95%, negative predictive value 74.83%] and >1.93 [specificity 90%, positive predictive value 95.85%)]. The proportion of patients in the indeterminate -zone using BAVENO VII criteria (48%) was significantly higher than that with VITRO (22%, P < 0.001). As many as 81.3% patients lying in the intermediate zone using BAVENO VII criteria could be recategorized as ruled-out or ruled-in using VITRO.
CONCLUSION: Blood group O did not affect vWF levels in our cohort of cACLD patients. VITRO holds promise as potential blood-based adjunct to elastography for assessment of CSPH and varices in cACLD.
CLINICAL TRIAL REGISTRATION: Not applicable.
METHODS: One hundred patients with cACLD were prospectively included. Hemogram, blood biochemistry, plasma vWF antigen levels, computed tomography abdomen, LSM with vibration-controlled transient elastography and endoscopic screening for varices were performed. CSPH was defined by the presence of collaterals on imaging, varices on endoscopy or portosystemic pressure gradient >10 mmHg.
RESULTS: vWF antigen levels were comparable between blood group O and non-O (282.9 ± 44.6% vs 289.9 ± 86.3%, P = 0.60). vWF: antigen had significant correlation with LSM [rho:0.65 (95% confidence interval (CI): 0.48-0.75, P < 0.001)] and portosystemic pressure gradient [rho = 0.60 (95% CI: 0.27-0.81, P < 0.001)].Areas under the curves (AUROCs) of LSM (0.878, 95% CI: 0.747-0.980) and VITRO (0.881, 95% CI: 0.745-0.982, P = 0.95) were comparable for detecting CSPH. Optimal VITRO rule-out and rule-in cut-offs for CSPH were <1.14 [sensitivity 95%, negative predictive value 74.83%] and >1.93 [specificity 90%, positive predictive value 95.85%)]. The proportion of patients in the indeterminate -zone using BAVENO VII criteria (48%) was significantly higher than that with VITRO (22%, P < 0.001). As many as 81.3% patients lying in the intermediate zone using BAVENO VII criteria could be recategorized as ruled-out or ruled-in using VITRO.
CONCLUSION: Blood group O did not affect vWF levels in our cohort of cACLD patients. VITRO holds promise as potential blood-based adjunct to elastography for assessment of CSPH and varices in cACLD.
CLINICAL TRIAL REGISTRATION: Not applicable.